Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.

FDA Clears Phase 2 Trial of Lorundrostat for Obstructive Sleep Apnea and Hypertension

Videos

The chief of neuroinfectious diseases and global neurology at Northwestern Medicine discussed a recently published study that highlighted Long COVID’s significant clinical and societal impact. [WATCH TIME: 5 minutes]

Impact of COVID-19 Vaccination on Neurologic Manifestations of Long COVID: Igor Koralnik, MD

In the pivotal phase 3 Clarity AD trial, treatment with a subcutaneous autoinjector of lecanemab led to reduced rates of amyloid-related imaging abnormalities while maintaining similar bioequivalence levels to the original formulation.

FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab

The founding director of the Optimal Aging Institute at the NYU Grossman School of Medicine talked about a recent study that estimated the lifetime risk of dementia and its implications for prevention, care, as well as societal planning. [WATCH TIME: 5 minutes]

Understanding Lifetime Risk and the Rising Burden of Dementia: Josef Coresh, MD, PhD

Founding director of the Optimal Aging Institute at the NYU Grossman School of Medicine.

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.

Optimizing Epilepsy Treatments: Stiripentol’s Role in Dravet Syndrome

, has been with the team since September 2022. Follow her on Twitter 

A duo of experts from NYU Grossman School of Medicine talked about a new study that identified deficiencies in acetyl-L-carnitine and free carnitine as potential blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

Mitochondrial Molecules Linking to Alzheimer Disease Disparities in Gender: Betty Bigio, PhD; Carla Nasca, PhD

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry provided a clinical overview of preclinical research identifying a new receptor for nerve growth factor that plays an important role in pain signaling. [WATCH TIME: 4 minutes]

Discovering a New Receptor for Nerve Growth Factor: Nigel Bunnett, PhD, BSc

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AES 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

The Consortium of Multiple Sclerosis Centers

Clinical

Here's the latest multidisciplinary MS research published online first in the 

. Click the slide to view the corresponding research article.

SAP Partner

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

EMD-22-NRD0193 - /clinical/multiple-sclerosis

IJMSC Online First: March 2024